Kurse werden geladen...
Prognose
Für dieses Unternehmen liegen uns keine Analysten-Daten vor.
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
Beliebteste Broker
News
08.01. - 12:03 Uhr
IPO watch 2024: Which new stocks will hit the market?
Among 2023 IPOs, one of the top performers was RayzeBio Inc. NASDAQ: RYZB, a biotech that's out of play now because it's being acquired by Bristol Myers Squibb Co. NYSE: BMY. » Mehr auf marketbeat.com
27.12. - 12:50 Uhr
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceuticals “is potentially the sole remaining clinical-stage, targeted radiopharm player with a robust supply chain,” analysts said in a research note on Wednesday. » Mehr auf marketwatch.com
26.12. - 23:47 Uhr
Yes Virginia, There Is a Santa Claus Rally
The Russell is up an astounding +26% from late October, largely thanks to signaled interest rate cuts from the Fed in 2024. » Mehr auf zacks.com
Unternehmenszahlen
| (EUR) | Sep. 2023 | |
|---|---|---|
| Umsatz | 0,00 | - |
| Bruttoeinkommen | 0,00 | - |
| Nettoeinkommen | 17,18 Mio | - |
| EBITDA | 19,98 Mio | - |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 3,48 Mrd € |
Anzahl Aktien | 60,02 Mio |
52 Wochen-Hoch/Tief | 58,08 € - 16,68 € |
| Dividenden | Nein |
Beta | 0 |
KGV (PE Ratio) | 18,04 |
KGWV (PEG Ratio) | 0,13 |
KBV (PB Ratio) | 1,67 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
| Name | RayzeBio inc |
| CEO | Dr. Kenneth Song M.D. |
| Industrie | Chemikalien |
| Börsengang | 15.09.2023 |
| Mitarbeiter | 88 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | RYZB |
Assets entdecken
Shareholder von RayzeBio inc investieren auch in folgende Assets
-
-
-
-
-
-
-
-
-
-